Next Article in Journal
The Vestigial Esterase Domain of Haemagglutinin of H5N1 Avian Influenza A Virus: Antigenicity and Contribution to Viral Pathogenesis
Next Article in Special Issue
Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis
Previous Article in Journal
Cytokines IL-17, TNF and IFN-γ Alter the Expression of Antimicrobial Peptides and Proteins Disparately: A Targeted Proteomics Analysis using SOMAscan Technology
Previous Article in Special Issue
Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress
Article Menu

Export Article

Open AccessReview
Vaccines 2018, 6(3), 52; https://doi.org/10.3390/vaccines6030052

Next Generation Cancer Vaccines—Make It Personal!

1
Drug Development Unit, Royal Marsden Hospital and The Institute of Cancer Research, Sutton SM2 5PT, UK
2
Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz, 8010 Graz, Austria
*
Author to whom correspondence should be addressed.
Received: 8 June 2018 / Revised: 23 July 2018 / Accepted: 7 August 2018 / Published: 9 August 2018
(This article belongs to the Special Issue Therapeutic Vaccines and Cancer Immunotherapy)
Full-Text   |   PDF [463 KB, uploaded 9 August 2018]   |  

Abstract

Dramatic success in cancer immunotherapy has been achieved over the last decade with the introduction of checkpoint inhibitors, leading to response rates higher than with chemotherapy in certain cancer types. These responses are often restricted to cancers that have a high mutational burden and show pre-existing T-cell infiltrates. Despite extensive efforts, therapeutic vaccines have been mostly unsuccessful in the clinic. With the introduction of next generation sequencing, the identification of individual mutations is possible, enabling the production of personalized cancer vaccines. Combining immune check point inhibitors to overcome the immunosuppressive microenvironment and personalized cancer vaccines for directing the host immune system against the chosen antigens might be a promising treatment strategy. View Full-Text
Keywords: cancer vaccines; immunotherapy; combination strategies; cancer immunity cycle; neoantigens; personalized cancer vaccine cancer vaccines; immunotherapy; combination strategies; cancer immunity cycle; neoantigens; personalized cancer vaccine
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Terbuch, A.; Lopez, J. Next Generation Cancer Vaccines—Make It Personal! Vaccines 2018, 6, 52.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top